Danaparoid dosing during continuous venovenous hemofiltration - a randomized controlled pilot study investigating two danaparoid dosing schemes with a standard heparin dosing scheme

Danaparoid dosing during continuous venovenous hemofiltration - a randomized controlled pilot study investigating two danaparoid dosing schemes with a standard heparin dosing scheme - Danaparoid CVVH trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30497

Enrollment

Registered

2007-10-18

Start date

2007-10-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute kindey failure Acute renal failure

Interventions

After having obtained informed consent, eighteen critically ill patients with acute renal failure needing CRRT will be randomized into 3 groups receiving either danaparoid or unfractionated heparin

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Critically ill patients with acute renal failure, needing CRRT.

Exclusion criteria

Exclusion criteria: -No informed consent -Use of unfractionated heparin or low molecular weight heparin in therapeutic doses within 24 hours before enrollment -Extreme coagulation disorders, such as platelet count 20 sec or APTT > 80 sec.

Design outcomes

Primary

Measure	Time frame
Area under the curve of serial anti-Xa measurements Circuit survival time *Occurrence and severity of bleeding events	—

Secondary

Measure	Time frame
markers of thrombin generation (e.g. thrombin-antithrombin complexes, prothrombin fragment F1+2 and endogenous thrombin potential)	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)